What actually happens after your first Wegovy pen

Why the first pen is built for adjustment, not weight loss

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Average weight loss at 2.4 mg maintenance dose was around 15% of body weight. That result, however, was built over the full titration period. The 0.25 mg starting phase contributed almost nothing to it numerically; its job was to reduce early nausea so that participants could reach the doses that actually work.

Semaglutide slows gastric emptying and acts on appetite-regulating receptors in the brain. At 0.25 mg, receptor engagement is enough to cause side effects in some people, but not enough to drive sustained appetite suppression. Think of it less as treatment and more as acclimatisation. If you feel next to nothing after pen one, that is not a sign it is not working; it is the protocol doing exactly what it was designed to do.

The NHS medicines page for semaglutide confirms that 0.25 mg is the starting dose and that treatment is escalated over several months. Weight loss becomes more noticeable once patients reach and sustain the higher maintenance doses.

Side effects in the first pen: what the pattern looks like

Nausea is the most commonly reported side effect in the early weeks of Wegovy. Vomiting, loose stools, constipation, burping and reflux also appear in trial data, and tend to be most prominent when a new dose level begins. That means pen one can be the roughest point for some people, precisely because the gut has not yet adapted.

Most of these effects are mild to moderate and settle within days to two weeks. Eating smaller meals, avoiding fatty or rich food, and staying well hydrated all help. If symptoms are severe or persistent, your prescriber needs to know, dose increases should not go ahead while significant side effects are ongoing, and pausing at 0.25 mg for an extra four weeks is a recognised and clinically reasonable option.

One thing worth knowing before your pen arrives: Wegovy is dispatched refrigerated, and your DPD tracking link will show you exactly when it is on the way. The box is plain and unbranded. Once it is in your fridge, the Patient Information Leaflet inside gives the precise storage rules for once it is out of the cold, always that leaflet, rather than a general estimate, for the accurate window.

For a broader look at how the full titration schedule unfolds, the Wegovy doses guide covers each escalation step in detail.

How week five usually differs from week one

Pen two, at 0.5 mg, is where many people report their first real changes to appetite. Portions that would once have felt comfortable start feeling sufficient sooner; hunger between meals can become less insistent. This is not guaranteed and varies considerably between individuals, but it matches what trial data show: measurable caloric reduction begins in earnest during the 0.5–1.0 mg phase, well before the 2.4 mg maintenance dose is reached.

If you are curious what the trajectory looks like through pen two and beyond, the second-pen experience page goes into more detail on what changes and why. For those further along, there is also a page covering how things typically look after four pens, when participants in the STEP 1 trial were reaching 1.0 mg.

A clinical point worth flagging: the NHS England weight management injections guidance recommends that if you lose less than 5% of body weight after six months at the maintenance dose, continuing treatment should be reviewed with your prescriber. That threshold applies to the full programme, not to the first pen, it would be clinically meaningless to judge effectiveness this early.

What this means before you start, or if you are considering it

Wegovy is a prescription-only medicine. A prescriber assesses your full clinical picture (weight history, any weight-related conditions, other medicines, contraindications) before treatment begins, and continues to review at each repeat. The first pen is part of a supervised journey, not a standalone trial run. If you want to understand exactly how a single Wegovy pen delivers its four doses, that detail can help set realistic expectations from the outset.

Semaglutide is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability; that is what the clinical assessment is for. Some people also wonder what to expect after completing just one dose of their Wegovy pen, particularly if side effects appear quickly or if they feel little difference at first. Others who are a little further into their first pen find it useful to read about what typically happens after three doses of a Wegovy pen, as that point often marks a shift in how the body is tolerating the medication.

Our clinical team at nume includes GPhC-registered Independent Prescribers who review every consultation personally. There is no algorithm deciding; a real clinician reads your answers the same day. If you are weighing up whether Wegovy might suit your situation, or want to explore treatment options more broadly, you can find an overview at our weight-loss treatment page. When you are ready, start your free consultation and a prescriber will take it from there.